MedTech deals this week shine a light on where innovation is heading – smarter surgery, safer sterilization, sharper diagnostics, and connected care at home. Ronovo Surgical’s $67m round was a highlight, but the smaller rounds are also key in accelerating change across the healthcare landscape.
Elutia sells drug-eluting bioenvelope tech to Boston Scientific for $88M
Elutia announced that it agreed to sell its bioenvelope technologies to Boston Scientific for $88 million. The company agreed to sell its EluPro and CanGaroo drug-eluting bioenvelopes in the cash deal. It designed these technologies to protect patients receiving implantable medical devices.
The deal underscores the value of its proprietary drug-eluting biologic technology platform. It also allows the company to complete the development and commercialization of its near-term pipeline without the need for shareholder dilution.
CEO Randy Mills
Last week’s tracker: Galvanize, ViCentra, and more
Ronovo Surgical raises $67M for surgical robot, signs J&J collaboration
Ronovo Surgical announced today that it closed its Series D financing round with a total investment of $67 million. Johnson & Johnson’s corporate venture capital organization, JJDC, led the financing. With the Series D closing, Ronovo also signed a targeted collaboration agreement with J&J to advance its surgical robot commercialisation efforts in China.
The collaboration offers hospitals in portions of China the advantages of the Carina modular robotic surgery platform, along with complementary J&J MedTech surgical technologies.
Founder, Chair and CEO John Ma
Noxilizer expands access to commercial-scale nitrogen dioxide terminal sterilization capacity with $30 Million
Noxilizer, the leader in nitrogen dioxide-based terminal sterilization for biopharmaceutical and medical device products, announced a growth capital financing of $30 million led by NewVale Capital, a growth equity firm focused on the pharmaceutical services sector.
This growth financing will expand access to Noxilizer’s NO₂ sterilization platform to meet growing global demand.
President and CEO Christopher Thatcher
MadSci announces US$10 million seed financing to advance SmartShunt hydrocephalus treatment
Madison Scientific announced that aggregate target proceeds for its seed round have been increased by US$3 million in order to accommodate “overwhelming” investor support and accelerate development of the company’s SmartShunt hydrocephalus management system.
Earlier this year, MadSci announced a US$7 million seed financing round co-led by Warf Ventures and two other investors.
CEO Tyler Wanke
SafeHeal raises €10M Series C extension for colorectal surgery device
Paris-based MedTech startup SafeHeal secured a €10 million extension to its Series C funding round. Asabys Partners, via its Sabadell Asabys II fund, led this additional investment. This funding aims to transform colorectal surgery for cancer patients.
The €10 million extension builds on an oversubscribed €35 million Series C round. This new capital will accelerate SafeHeal’s pivotal U.S. IDE study.
CEO Chris Richardson
Fraiya launches NHS trial of AI pregnancy ultrasounds after £3.5M funding and CE marking
Fraiya launched a multi-center NHS trial of its AI-powered pregnancy ultrasound technology, following CE marking approval and completion of a £3.5 million pre-seed funding round backed by RAW Ventures, Cedars-Sinai Ventures, and healthcare-focused angel investors.
The company will test its FraiyaScan system across four NHS hospitals with over 9,500 pregnant women.
CEO Reza Razavi
Nuwellis secures NIH grant to advance pediatric kidney device
Nuwellis announced the National Institutes of Health awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies, to develop continuous renal replacement therapy for kids.
The program will support the development of the Vivian CRRT system, designed for children weighing under 20 kg. The funding will also advance software and firmware across the company’s broader platform.
CEO John Erb
IMMA Health secures $1.6M grant for at-home fertility monitoring device
Israeli healthtech startup IMMA Health secured a $1.6 million grant from the Israel Innovation Authority while earning the Seal of Excellence from the European Innovation Council. The company is developing the world’s first self-operated transvaginal ultrasound solution for at-home fertility monitoring.
The funding will support further development of the device and regulatory approval processes.
Co-Founder and CEO Beatrice Chemla
